摘要
WHO于2020年发布的WHO国家药品定价政策指南中提到的10种定价方法是国际常用的定价方法。但由于中成药成本构成比例的特殊性,单纯参照化药及生物药品制品对中成药进行定价存在适用性偏差。当前,我国药品定价主要方法为内部参考定价、招标谈判定价、促进使用有质量保证的仿制药和生物类似药、汇总采购等方法。文章在系统分析各种定价方法的基础上,明确其对于中成药医保定价的适用性及其原因,其中价值定价和提高价格透明度的方法有助于提高中成药医保定价的合理性。
WHO Guideline on Country Pharmaceutical Pricing Policies,published in 2020,outlines 10 commonly used pricing methods internationally.However,due to the unique composition of costs for traditional Chinese medicine(TCM),directly applying pricing methods designed for chemical and biological drugs may lead to discrepancies.Currently,in China,drug pricing primarily in-volves internal reference pricing,tender negotiation pricing,promoting the use of quality-assured generic and biosimilar drugs,and centralized procurement.It systematically analyzes various pricing methods and identifies their applicability and underlying reasons concerning the pricing of TCM within the medical insurance system.The method of value-based pricing and increasing price transparency has advantages for the pricing regulation of traditional Chinese medicine under medical insurance.
作者
杨一玖
刘斌
张海力
梁宁
宋填
曹文杰
李慧珍
宗星煜
王巍力
王丁熠
胡紫腾
王燕平
韩晟
史楠楠
Yang Yijiu;Liu Bin;Zhang Haili;Liang Ning;Song Tian;Cao Wenjie;Li Huizhen;Zong Xingyu;Wang Weili;Wang Dingyi;Hu Ziteng;Wang Yanping;Han Cheng;Shi Nannan(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing,100700,China;不详)
出处
《中国卫生经济》
北大核心
2023年第12期53-56,共4页
Chinese Health Economics
基金
国家自然科学基金面上项目(82174532)
中国中医科学院科技创新工程项目(CI2021A00702)
中国中医科学院中央级公益性科研院所基本科研业务费自主选题(ZZ14-FL-005)
国家中医药管理局青年岐黄学者项目(Z0841)。
关键词
WHO
中成药定价
价值定价
综述
World Health Organization
pricing of traditional Chinese medicine
value-based pricing
review
